Coordinating Company-Driven Medical Education Programs

Coordinating Company-Driven Medical Education Programs


Coordinating Company-Driven Medical Education Programs is the seventh module of the 10-part Medical Affairs Product Launch Series. This module contains best practices and benchmarks associated with company-driven medical education activities that occur as part of medical affairs’ contribution to product launch.

To learn more about the other modules in the Medical Affairs Product Launch Series and the benefits of subscribing to the entire series, click here.




  • Description
  • Additional information

Coordinating Company-Driven Medical Education Programs

Coordinating Company-Driven Medical Education Programs is the seventh module of the 10-part Medical Affairs Product Launch Series. Based on primary research collected directly from executives leading top medical affairs teams, this module examines company-driven medical education team budgets and staffing levels across product lifecycle stages. Data reveal the lifecycle stage that company-driven medical education programs begin based on the type of product it supports.

It also explores company-driven medical education teams’ resources and activity levels throughout the launch window. It examines how budget levels, staffing and event levels change as products advance through the lifecycle.  In developing this module, Cutting Edge Information’s analysts collected surveys from and consulted with a series of medical affairs leaders at several top pharmaceutical, biotechnology and medical device companies.

  • Publication Date: July 2017
  • Pages: 34
  • Figures: 20+

Determine the most effective time to start company-driven medical education activities: When teams design their company-driven medical education programs, an important decision to be made is which lifecycle stage to begin. The stage in which a team decides to start company-driven medical education activities varies greatly depending on the type of product it supports. This module uncovers when surveyed teams have started their company-driven medical education activities at each lifecycle stage, broken down by product type.


Benchmark medical education budget and staffing levels throughout the product launch window: Medical education team budgets and staffing levels depend on factors such as product type and market region. Data show that a key indicator of the priority companies place on company-driven medical education is the budget dedicated to the activities. Staffing — and deciding when outsourcing is necessary — is an important resource for medical education teams. Use this module’s benchmarks to determine the budget size and staffing levels that would best support your company’s product launches throughout the launch window.

Measure team success using an assortment of key performance indicators (KPIs): The use of KPIs to measure team success remains crucial. One of the most important KPIs is the number of company-driven medical education events, both in-person and on-line, that the team executes. Proving the value of these activities can be difficult since it does not link directly to sales. Use this study to see the assortment of KPIs that companies use to evaluate their company-driven medical education team operations.


Drug company employees involved in the following areas should consider purchasing this report:
– Medical affairs
– Medical education
– Scientific affairs
– Scientific programs
– CME grants funding


The traditional goal of company-driven or unaccredited medical education is primarily to help educate physicians and other healthcare providers (HCPs) about diseases, treatments and new clinical practices. But an interviewed Company C vice president from a small US team believes that medical education team objectives are shifting. According to this VP, medical education teams are beginning to focus more on providing value to HCPs and educating them about significant trends within the pharmaceutical industry. Concentrating on the larger problems surrounding health and wellness, rather than on just the diseases that companies’ drugs will ultimately treat, allows pharmaceutical companies to increase their worth to physicians.